Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Novo Nordisk Convenes Policy And Clinical Experts At Diabetes Media Summit
A distinguished panel of clinical and policy experts gathered by Novo Nordisk recently convened in Washington, D.C. to explore solutions to address the exponential growth of diabetes in America. The universal theme from the renowned speakers, including Larry Hausner, CEO of the American Diabetes Association (ADA), was that the cost of the disease to our nation, at $218 billion annually, is startling and the lag in patient motivation to take action to offset the disease is distressing. Without intervention at both a national and patient level, our nation runs the risk of reaching a projected 50 million Americans having diabetes by the year 2025.
generic viagra online
Swine Flu Expected To Continue Through The Summer, US
Health officials said on Thursday that it looks like the novel H1N1 swine flu virus will continue to spread in the US through the summer months,
News of the day
Toxic Immune-Suppressing Drugs Replaced By Post-Transplant Combo In Monkeys
Transplant patients rely on drugs to prevent graft rejection, but at the cost of serious side effects. The class of immunosuppressive drugs known as calcineurin inhibitors (examples are cyclosporine and tacrolimus) can damage patients" kidneys and lead to high blood pressure, among other problems.
Oncology

Toward New Drugs That Turn Genes On And Off

Scientists in Michigan and California are reporting an advance toward development of a new generation of drugs that treat disease by orchestrating how genes in the body produce proteins involved in arthritis, cancer and a range of other disorders. Acting like an "on-off switch," the medications might ratchet up the production of proteins in genes working at abnormally low levels or shut off genes producing an abnormal protein linked to disease. Their report is in the current issue of ACS Chemical Biology, a monthly journal. In the study, Anna K. Mapp and colleagues discusses molecules that cause genes to be active and churn out proteins - so-called transcriptional activators. That"s because they control a key process known as transcription, in which instructions coded in genes produce proteins. Malfunctions in these activators could lead to altered transcription patterns that lead to disease. For example, variations in the tumor suppressor gene p53 are found in more than half of all human cancers. Mapp describes discovery of a group of molecules that could be used to help scientists better understand transcription. Known as activator artificial transcriptional activation domains, these small molecules mimic natural activators and could provide insights on how mistakes in gene regulation result in various diseases. "Evidence suggests that these small molecules mimic the function and mechanism of their natural counterparts and present a framework for the broader development of small molecule transcriptional switches," Mapp states. Article: "Amphipathic Small Molecules Mimic the Binding Mode and Function of Endogenous Transcription Factors" http://pubs.acs.org/stoken/presspac/presspac/full/10.1021/cb900028j Contact: Anna K. Mapp, Ph.D. University of Michigan Ann Arbor, Mich. Michael Woods American Chemical Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009